BTIG Starts Checkmate Pharmaceuticals (CMPI) at Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
UPDATE: BMO Capital Starts Checkmate Pharmaceuticals (CMPI) at Outperform
September 1, 2020 4:09 AM EDT(Updated - September 1, 2020 5:02 AM EDT)
(updating comment)
BMO Capital analyst Do Kim initiates coverage on Checkmate Pharmaceuticals (NASDAQ: CMPI) with a Outperform rating and a price target of $32.00.
The analyst comments "We believe lead drug CMP-001 is the best TLR9... More
